Shame about the strategy

29 Jun 2004 By Robert Cyran

Such a deal would bulk up the German conglomerate’s OTC drugs business and reduce combined costs. But the deal must not distract from bigger strategic issues. The company needs to be broken up.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.